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Ocular involvement is a prominent clinical feature of mitochondrial disease. This can manifest as
optic nerve dysfunction speciﬁcally involving retinal ganglion cells as typiﬁed by Leber hereditary
optic neuropathy (LHON), or progressive external ophthalmoplegia (PEO) and ptosis involving the
extraocular muscles which is commonly associated with either primary mitochondrial DNA
(mtDNA) mutations or acquired mtDNA defects secondary to a nuclear genetic disorder of
mtDNA maintenance. In this short review, we will outline the unique characteristics of mitochon-
drial genetic disease and its investigation with reference to the clinical features and molecular
genetic abnormalities underlying mitochondrial ophthalmological disease.
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Mitochondrial diseases are a clinically multifarious group of
genetic disorders that affect organs heavily dependent on
aerobic metabolism with extensive phenotypic and disease
burden variability (McFarland et al., 2010). Neuro-
ophthalmic manifestations of mitochondrial disorders are
common and include retinal, macular and optic nerve
dysfunctions, external ophthalmoplegia with ptosis and retro-
chiasmal visual loss. Ocular features are rarely in isolation
and may be associated with neurological and/or systemic
symptoms. The differential diagnosis of ocular muscle
dysmotility is broad and includes ocular myasthenia, ocular
myositis, thyroid associated orbitopathy, congenital cranial
dysinnervation disorders, oculopharyngeal muscular dystro-
phy and other neurodegenerative or dystrophic disorders
(Schoser and Pongratz, 2006). This review article highlights
the salient clinical and molecular features of ocular manifesta-
tions of mitochondrial diseases.
1.1. Basic mitochondrial genetics
Mitochondria are responsible for producing >90% of a cell’s
ATP through the pathways of electron transfer and oxidative
phosphorylation (OXPHOS) that comprise the respiratory
chain. The only location of extrachromosomal DNA within
the cell, mitochondria are under the dual genetic control of
both nuclear DNA and the mitochondrial genome (mtDNA),
a small (16.6 kb) multicopy, double-stranded circular DNA
molecule which encodes 13 essential polypeptides of the respi-
ratory chain and the necessary RNA machinery for their trans-
lation (Fig. 1). The remaining protein subunits that make up
the respiratory chain complexes, together with many hundreds
of other proteins found within the organelle – many of which
are required for mtDNA maintenance, replication and the
translation of mitochondrial proteins – are synthesised oncytoplasmic ribosomes and speciﬁcally targeted and sorted to
their correct mitochondrial location.
The mitochondrial genome possesses unique characteristics
that distinguish it from Mendelian genetic rules (Taylor and
Turnbull, 2005). It is strictly maternally-inherited, and is poly-
ploid, i.e. multiple copies of mtDNA are present within each
mitochondrion with several thousands present in individual
cells. Normally, all of the mitochondrial genomes within an
individual are identical, a situation termed homoplasmy. How-
ever, a mutation occurring in one copy of mtDNA can eventu-
ally lead to dual populations of wild type and mutated
mtDNA coexisting within the same cell – heteroplasmy. At
mitosis, both wild-type and mutated mtDNA are randomly
segregated to each daughter cell, thereby affecting both disease
expression and inheritance, further contributing to the wide
range of clinical presentations seen in mtDNA disorders. The
majority of deleterious mtDNA mutations are heteroplasmic,
with clinical manifestations only becoming evident when the
number of mutated mtDNA molecules exceeds a critical
‘threshold’. This threshold varies between organs depending
upon their energy requirements, and reﬂects the incapacity of
the remaining wild type mtDNA to compensate for the
mutated mtDNA, leading to OXPHOS impairment and conse-
quently cellular (routinely demonstrated by the histocytochem-
ical assessment of cytochrome c oxidase (COX) activity) and
organ dysfunction (see later). Although many important fac-
tors such as nuclear genetic background and mtDNA genotype
can inﬂuence the phenotypic effect of particular mtDNA
mutations, the relative abundance and speciﬁc tissue distribu-
tion of mutated mtDNAs are key determinants of the severity
of the resulting clinical phenotype.
1.2. The laboratory diagnosis of mitochondrial disease
The laboratory diagnosis of mitochondrial disease is far from
straightforward; mtDNA heteroplasmy, the lack of clear geno-
Figure 1 The human mitochondrial genome. Represented is a schematic diagram of the 16.6 kb circular, double-stranded human
mitochondrial genome with an enhanced, linearised view of the D-loop and transcription termination regions. The outer circle represents
the heavy (H) strand of the genome and the inner circle the light (L) strand. Human mtDNA encodes the two mt-rRNA genes (shown in
red) RNR1 (12S rRNA) and RNR2 (16S rRNA), 22 mt-tRNAs (black bars) identiﬁed by their single letter abbreviation, and 13 essential
respiratory chain polypeptides: seven subunits (ND1–ND6 and ND4L) of complex I (green), CYTB of complex III (purple), three
catalytic subunits (COI–COIII) of complex IV (yellow) and ATP6 and ATP8 of complex V (blue). Major non-coding regions of the
genome (grey) include the origin of L-strand replication (OL) and the 1.1 kb D-loop in which the origin of H-strand replication (OH) and
regulatory elements and binding sequences for key factors involved in mtDNA transcription initiation and termination are located.
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involvement and the complex interactions between the nuclear
and mitochondrial genome are all contributing factors. The
majority of mitochondrial diagnostic reference laboratories
will often adopt a multidisciplinary approach, piecing together
information from clinical, histochemical and respiratory chain
enzyme testing to inform molecular genetic screening as guided
by rational diagnostic algorithms (McFarland et al., 2010).
Some patients with mitochondrial disease and ocular involve-
ment (e.g. Leber hereditary optic neuropathy (LHON)) can be
easily diagnosed by a simple DNA test using an EDTA-blood
sample. For others, however, as in the case of Chronic Pro-
gressive External Ophthalmoplegia (CPEO or PEO), the caus-
ative mtDNA mutation – or in the case of Mendelian PEO,
acquired mtDNA abnormalities (e.g. multiple mtDNA dele-
tions) which are secondary to the primary nuclear genetic de-
fect – may require the investigation of muscle biopsy tissue.
Many patients with mtDNA disease show histological and his-
tochemical changes indicative of OXPHOS dysfunction. Clas-
sically, these are ragged-red ﬁbres – so called because of the
appearance of ﬁbres on Gomori trichrome staining showing
subsarcolemmal accumulation of abnormal mitochondria –
and COX-deﬁcient ﬁbres which signal mtDNA involvement
(Fig. 2). mtDNA rearrangements (deletions and duplications)are assessed by Southern blotting or PCR-based strategies,
whilst sequencing the entire mitochondrial genome can be
undertaken relatively easily to identify rare or novel mtDNA
mutations when common mtDNA mutations have been ex-
cluded (McFarland et al., 2010). The phenotypic and geno-
typic variability associated with primary mtDNA mutations
(both point mutations and single, large-scale mtDNA deletion)
and ocular phenotypes is illustrated in Fig. 3.2. Ocular manifestations of mitochondrial disease
2.1. Chronic Progressive External Ophthalmoplegia (PEO)
with ptosis
CPEO, ﬁrst described in the late 19th century (Von Graefe,
1867) is characterised by bilateral, slowly progressive loss of
extraocular muscle mobility, orbicularis oculi weakness and
ptosis. Due to the insidious and often symmetrical nature of
onset, patients with PEO seldom complain of diplopia and
are often unaware of ocular restriction. In the early stages of
PEO, restriction is not always equal; however, as the disorder
progresses and the muscles become ﬁbrotic, near complete
ophthalmoplegia may ensue with relative sparing of downgaze
m.14710G>A, m.14723T>C
m.582T>C, m.611G>A, m.642T>C
m.8342G>A, m.8344G>A
m.8355T>C, m.8363G>A
m.3243A>G, m.3243A>T, m.3244G>A,
m.3251A>G, m.3255G>A, m.3256C>T,
m.3273T>C, m.3283G>A, m.3302A>G
m.3460G>A - LHON
m.11778G>A – LHON 
m.14484T>C – LHON
m.12276G>A, m.12294G>C,
m.12315G>A, m.12316G>A
4,977-bp 
ΔmtDNA
m.4267A>G, m.4272T>C, m.4284G>A,
m.4298G>A, m.4302A>G, m.4308G>A, 
m.4309G>A, m.4315delA
m.8993T>G/C – Retinitis
Pigmentosa (NARP phenotype)
m.7458G>A
m.5532G>A
OH
m.5628T>C, m.5636T>C
m.5814T>C
m.11232T>C
Figure 3 Pathogenic mtDNA mutations associated with ocular phenotypes. The circular, double-stranded human mitochondrial
genome is depicted with sites of common mtDNA mutations highlighted associated with LHON (the three primary mtDNA mutations in
the MTND1, MTND4 and MTND6 genes are shown in red), retinitis pigmentosa as a feature of the NARP phenotype (m.8993T>G/C
mutations shown in blue) or PEO and ophthalmoparesis (shown in black). These include single, large-scale mtDNA deletions (as
highlighted by the site of the 4977-bp ‘‘common’’ deletion), rare mutations in mitochondrial RNA genes (e.g. m.11232T>C in MTND4)
or mitochondrial tRNA point mutations. Whilst these appear to be distributed amongst the tRNA genes, mutations in genes encoding mt-
tRNALeu(UUR), mt-tRNALeu(CUN), mt-tRNAIle and mt-tRNALys are most prevalent.
Figure 2 Skeletal muscle histopathological abnormalities associated with pathogenic mtDNA mutations. The histological and
histochemical assessments of skeletal muscle may provide useful clues in determining mtDNA involvement in disease pathology. Shown is
a sequential series of transverse-orientated muscle biopsy sections from a patient with CPEO due to a mitochondria tRNA gene point
mutation, reacted for the following stains or enzyme activities: (a) modiﬁed Gomori trichome stain highlighting classical ragged-red
muscle ﬁbres, in which abnormal mitochondrial accumulate around the subsarcolemmal region; (b) SDH, which further accentuates the
subsarcolemmal accumulation of mitochondrial enzyme activity; (c) COX histochemistry showing pale-reacting COX-deﬁcient ﬁbres
within a population of normal ﬁbres, a typical ‘‘mosaic’’ distribution; (d) sequential COX/SDH histochemistry highlighting individual
COX-deﬁcient ﬁbres which retain SDH activity (blue) against a background of ﬁbres with normal COX activity (brown).
398 G.S. Gorman, R.W. Taylor(Fig. 4) (Schoser and Pongratz, 2006). Pupillary response and
accommodation remain intact, and unlike supranuclear gaze
palsies, PEO remains unchanged on oculocephalic maneuver
(doll’s eyes) and caloric testing.
When PEO and ptosis are associated with other neurologi-
cal or multisystem abnormalities, these may be termed ophthal-
moplegia-plus (PEO+) syndromes. A myriad of systemic
features have been reported and include limb, facial and bulbar
muscle weakness, short stature, diabetes mellitus, deafness, car-
diac conduction defects, central and peripheral respiratory dys-
function and endocrine and sex organ abnormalities (Biousseand Newman, 2001). Kearns–Sayre Syndrome (KSS) is the
most common form of a PEO+ syndrome (Kearns and Sayre,
1958). Its cardinal features include early age of PEO onset (be-
fore the age of 20 years), degenerative pigmented retinopathy
and cardiac conduction block with the risk of potentially life
threatening arrhythmias, cerebellar dysfunction or elevated
cerebrospinal ﬂuid protein (>100 mg/dl) (Rowland et al.,
1983). With disease progression, a proximal myopathy devel-
ops in addition to deafness, bulbar dysfunction, areﬂexia and
stroke-like episodes. Although reports of sibling pairs exist
(Rowland et al., 1988), most cases of KSS are sporadic.
Figure 4 The clinical, histochemical and mtDNA abnormalities associated with mitochondrial PEO. (A) Typical clinical features of a
patient with mitochondrial CPEO, extraocular motility in cardinal directions of gaze is severely reduced with relative preservation of
downgaze as the patient is asked to look down (i), up (ii), right (iii) and left (iv). (B) Sequential COX-SDH histochemistry showing the
presence of scattered COX-deﬁcient ﬁbres in a quadriceps muscle biopsy. (C) Southern blotting of muscle DNA indicates the patterns
observed in a control (lane 1), a patient with a heteroplasmic, single large-scale mtDNA deletion (lane 2) and multiple mtDNA deletions
(lanes 3 and 4). (D) Long-range PCR is also widely used to identify multiple mtDNA deletions (lane 3) which are ampliﬁed in addition to
full-length, wild type mtDNA. Also shown is a control (lane 2) and DNA size markers (lane 1).
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Late onset-PEO is the most common form of extraocular mito-
chondrial myopathy and often arises spontaneously, character-
ised by heteroplasmic, single large-scale mtDNA
rearrangements (predominantly mtDNA deletions but occa-
sionally associated duplications) and COX-deﬁcient ﬁbres in
skeletal muscle tissue (Fig. 4). The pathogenic mtDNA dele-
tion accounts for 20–90% of the total skeletal muscle mtDNA
(Biousse and Newman, 2001), although in some patients low
levels of mtDNA deletion have been reported (Schaefer
et al., 2005). Variability in the proportions of deleted mtDNA
present in different tissues may in part account for some of the
clinical aberration, but no clear correlation between the size
and site of the mtDNA rearrangement and biochemical and
phenotypic expression exists. Approximately 20% of patients
with PEO demonstrate a Mendelian pattern of inheritance,
implicating nuclear DNA abnormalities. Mendelian PEO can
be dominantly- or recessively-inherited, with patients exhibit-
ing COX-deﬁcient ﬁbres in muscle and a ‘‘laddering’’ of smal-
ler-sized, variable mtDNA deletions on either Southern blot or
long-range PCR analysis. In the absence of mtDNA rearrange-
ments (single or multiple mtDNA deletions), mtDNA point
mutations should also be investigated. The m.3243A>G
MTTL1 gene mutation, typically associated with the MELAS
phenotype, is a recognised cause of mitochondrial PEO (Kuncl
and Hoffman, 1999; Moraes et al., 1993) whilst discreet, rarer
mtDNA mutations can be found in mitochondrial-encoded
mRNA genes but more typically tRNA genes (Fig. 4). In many
cases, akin to single, large-scale mtDNA rearrangements, thecausative tRNA mutation arises sporadically, is not transmit-
ted and is often restricted to skeletal muscle (Fu et al., 1996;
Chinnery et al., 1997; Taylor et al., 1998, 2002; Karadimas
et al., 2002; Berardo et al., 2010).
Occasionally, the pathogenic tRNA mutation may be pres-
ent at very low levels in a diagnostic skeletal muscle biopsy
(Alston et al., 2010). The affected muscles in patients with
PEO are the extraocular muscles, which exhibit major biolog-
ical differences to other skeletal muscles. Recent studies have
shown that extraocular muscles readily accumulate mtDNA
mutations with age, indicative of an accelerated ageing process
(Yu-Wai-Man et al., 2010a) whilst in CPEO patients with pro-
ven mtDNA mutations, higher proportions of COX-deﬁcient
ﬁbres are present in extraocular muscle samples which have
been removed during corrective strabismus and ptosis surgery
compared to quadriceps muscle taken for diagnostic purposes
(Greaves et al., 2010) (Fig. 5).
2.1.2. Autosomal dominant (ad)PEO
The majority of families with autosomal dominant PEO (ad-
PEO) harbour mutations in one of the following genes: POLG
encoding the catalytic subunit of mitochondrial pol c (Van
Goethem et al., 2001), PEO1 encoding mitochondrial helicase
Twinkle (Spelbrink et al., 2001), SLC25A4 encoding adenine
nucleotide translocator 1 (Kaukonen et al., 2000) and RRM2B
encoding a subunit of the p53-inducible ribonucleotide reduc-
tase protein required for maintaining balanced mitochondrial
dNTP pools (Tyynismaa et al., 2009). Other mutated genes in-
clude POLG2, encoding the accessory beta-subunit of pol c
Figure 5 Vulnerability of extraocular muscles to mtDNA mutation accumulation. (A) The data shown in this panel highlight the
distribution of COX-deﬁcient extraocular muscle ﬁbres with age in a series of 46 normal human subjects (age range 3–96 years).
The simulated curve models an exponential increase in COX deﬁciency with normal aging (r2 = 0.5753) whilst the dotted lines accentuate
the predicted upper and lower 95% conﬁdence range within this group. Data are reproduced from Yu-Wai-Man et al. (2010a) with
permission. (B) Enhanced mitochondrial histochemical abnormalities are evident in extraocular muscle compared to skeletal muscle
(quadriceps) biopsies in patients with mitochondrial CPEO. Illustrated is sequential COX/SDH histochemistry on paired muscle samples
from patients with a mitochondrial tRNA point mutation (m.4298G>A) (a and b), a single, large-scale 5.0 kb mtDNA deletion (c and d)
and multiple mtDNA deletions secondary to a p.R334Q PEO1 (Twinkle) gene mutation (e and f). A comparison of the percentage of
COX-deﬁcient ﬁbres between skeletal muscle and extraocular muscles in a panel of 13 mitochondrial CPEO patients reveals a signiﬁcantly
higher percentage of COX-deﬁcient ﬁbres in extraocular muscle compared to skeletal muscle (p< 0.0001) (g). Data are reproduced from
Greaves et al. (2010) with permission.
400 G.S. Gorman, R.W. Taylor(Longley et al., 2006) and OPA1 which encodes a dynamin-
related GTPase required for mitochondrial dynamics and also
mtDNA maintenance (Hudson et al., 2008; Amati-Bonneau
et al., 2008). Mitochondrial Twinkle helicase mutations, which
also underlie autosomal recessive infantile onset spinocerebel-
lar ataxia (IOSCA) and mtDNA depletion syndromes, are a
common cause of late-onset adPEO, characterised by the accu-
mulation of variable, large-scale mtDNA deletions in muscle
over time. PEO1 gene mutations are associated with a predom-
inantly myopathic phenotype with mild multisystem involve-
ment (Fratter et al., 2010), somewhat in contrast to POLG
mutations which are the most common cause of PEO and mul-
tiple mtDNA deletions but are associated with a broad clinical
spectrum (Horvath et al., 2006).
2.1.3. Autosomal recessive (ar)PEO
Autosomal recessive PEO cases have been reported in pedigrees
harbouring mtDNA rearrangements in skeletal muscle, and are
particularly associated POLG mutations (reviewed in
Copeland, 2008). Recessive mutations in the POLG gene also
cause the sensory ataxia neuropathy, dysarthria and ophthalm-oparesis (SANDO) phenotype (Fadic et al., 1997) and mito-
chondrial recessive ataxia syndrome (MIRAS) (Winterthun
et al., 2005) in addition to arPEO.
2.2. Other mitochondrial myopathies associated with CPEO
2.2.1. Mitochondrial encephalomyopathy with lactic acidosis and
stroke-like episodes (MELAS)
Rarely, CPEO may occur in patients with MELAS (mitochon-
drial encephalopathy, lactic acidosis, stroke-like episodes). As
mentioned brieﬂy, there is a subset of patients with PEO who
harbour the m.3243A>G point mutation typically associated
with MELAS but who manifest no other clinical features of
this condition (Kuncl and Hoffman, 1999). MELAS (Pavlakis
et al., 1984), which is classically associated with headaches,
vomiting, stroke-like episodes, focal neurological deﬁcits, sys-
temic lactic acidosis and evidence of mitochondrial dysfunc-
tion on muscle biopsy is usually associated with signiﬁcant
morbidity. MELAS may also be associated with other systemic
features including short stature, deafness, diabetes and
seizures. Additional ocular manifestations may include
Mitochondrial DNA abnormalities in ophthalmological disease 401pigmentary retinopathy and maculopathy. MELAS symptoms
commonly begin before the age of 15 years but reports of dis-
ease manifestations as late as the ﬁfth decade have been docu-
mented. Brain imaging often shows basal ganglia calciﬁcation
with white matter lesions apparent in cases of repeated epi-
sodes of headaches, vomiting, seizures or focal neurological
symptoms. Muscle biopsy can show classical mitochondrial
abnormalities (ragged-red ﬁbres, COX-deﬁcient ﬁbres)
although that may be normal. Molecular conﬁrmation of the
m.3243A>G mutation can be made through mtDNA analysis
of blood, muscle or urine with urinary m.3243A>G hetero-
plasmy levels shown to be a good clinical correlate of central
disease manifestations (Whittaker et al., 2009).
2.2.2. Myoclonic epilepsy, myopathy with ragged-red ﬁbres
(MERRF)
CPEO has also been described in myoclonic epilepsy, myopa-
thy with ragged-red ﬁbres (MERRF), a mitochondrial cytopa-
thy characterised by myoclonic epilepsy, myopathy and a
progressive cerebellar syndrome (Fukuhara et al., 1980). Other
clinical features may include deafness, optic atrophy, Wolf
Parkinson White Syndrome, peripheral neuropathy and
dementia. Creatine kinase and serum lactate may be moder-
ately elevated, whilst brain imaging may simply show mild dif-
fuse atrophy only. Molecular conﬁrmation can be made by
screening the m.8344A>G mutation in blood.
2.2.3. Mitochondrial neurogastrointestinal encephalomyopathy
(MNGIE)
Mutations in the nuclear-encoded TYMP gene encoding
thymidine phosphorylase may result in mitochondrial neuro-
gastrointestinal encephalomyopathy (MNGIE), a recessively-
inherited disorder that is associated with PEO and ptosis. It
is deﬁned clinically by cachexia, severe gastrointestinal dysmo-
tility, sensorimotor neuropathy, skeletal myopathy and leuko-
encephalopathy which may be associated with cognitive
decline (Nishino et al., 2000). MNGIE is often associated with
high morbidity and mortality with death usually ensuing in the
3rd or 4th decades of life. Deafness is common but ataxia and
seizures, which are common clinical associates of other mito-
chondrial myopathies, are typically absent. Ragged-red and
COX-deﬁcient ﬁbres are reported in muscle biopsies, which
also reveal multiple mtDNA deletions.
2.3. Neurogenic weakness, ataxia and retinitis pigmentosa
(NARP)
NARP is a clinical syndrome characterised by developmental
delay, pigmentary retinopathy, dementia, seizures, sensory
neuropathy, proximal myopathy, ataxia, migraine and deaf-
ness. Serum pyruvate and lactate may be normal, as are muscle
biopsy ﬁndings. Brain imaging, if abnormal, may only show
non-speciﬁc cerebral or cerebellar atrophy in patients with
high disease burden. The majority of cases exhibit mutation
at m.8993 in the MTATP6 gene, easily detectable in the blood
DNA given there is an excellent correlation between mutation
load and clinical severity.
2.4. Pigmentary retinopathy
Pigmentary retinopathy is not infrequent in mitochondrial
disease with classical ‘salt and pepper’ appearances onfundoscopic evaluation (Isashiki et al., 1998; Kerrison et al.,
2000; Ortiz et al., 1993). Frequently this is only present as ﬁne
pigment dusting in the periphery, necessitating formal indirect
ophthalmoscopy for accurate detection and evaluation. The
early features of mitochondrial-related pigmentary retinopathy
are somewhat different from classical retinitis pigmentosa
which is associated with a bony spicule pattern of pigmenta-
tion; however, with disease and patient age progression, this
latter pattern of retinopathy may emerge (Kerrison et al.,
2000). Vascular attenuation is common with mild visual loss
occurring in up to half of those affected. Although pigmentary
retinopathy is recognised as a cardinal feature of KSS, it can
also occur in MELAS, MIDD, OPA1 mutation (Hudson
et al., 2008) and NARP (Kerrison et al., 2000).
Bilateral macular dystrophy has been recognised in MIDD
(maternally-inherited diabetes and deafness) andMELAS asso-
ciated with the m.3243A>Gmutation (Ambonville et al., 2008;
Adjadj et al., 2008; Latkany et al., 1999; Latvala et al., 2002;
Massin et al., 1995, 1999; Michaelides et al., 2008; Smith
et al., 1999) (Fig. 6A). Fundus autoﬂuorescence characteristics
are distinctive from most other dystrophies, with a notable dis-
crepancy between the size of abnormal autoﬂuorescence and
that which would be suggested from fundoscopic appearance.
The most common pattern of m.3243A>G mutation-associ-
ated macular dystrophy is circumferentially-distributed perifo-
veal atrophy with central fovea sparing. Pale deposits and
granularity at the level of the retinal pigment epithelium and
subretinal pigment clumping is evident adjacent to the areas
of atrophy. A subtype of maculopathy consistent with a pattern
dystrophy is described with no perifoveal atrophy andmore dif-
fuse speckled appearance of the macula (Michaelides et al.,
2008; Rath et al., 2008).
2.5. Leber hereditary optic neuropathy (LHON)
Leber hereditary optic neuropathy (LHON) is the commonest
primary mitochondrial disease associated with bilateral optic
neuropathies (Newman, 2005; Riordan-Eva et al., 1995;
Yu-Wai-Man et al., 2009). It is recognised as the most frequent
cause of isolated blindness in young men with estimated point
prevalence of 1 in 31,000 (Man et al., 2003). Maternally-trans-
mitted LHON pedigrees show incomplete penetrance with a
male preponderance for visual loss (3:1 male to female ratio).
The reason for this remains unknown but an X-linked nuclear
modiﬁer has been proposed. Age of onset is variable ranging
from the ﬁrst to eighth decade, but most cases present in their
late teens and twenties.
Visual loss associated with LHON is characteristically sub
acute, central and painless. In most cases visual loss occurs
in one eye, followed sequentially in the other eye with a median
interim period of 8 weeks but this can range from days to years
(Riordan-Eva et al., 1995). Typically visual loss occurs in iso-
lation – pedigrees are otherwise clinically asymptomatic – and
it may be severe, deteriorating in most patients to acuities of
20/200 (criteria to register blind) or worse. Visual ﬁeld defects
consistent with central or cecocentral defects are typical. Col-
our vision dysfunction may be an early and severe feature of
LHON-associated visual loss. Pupillary function is relatively
preserved. Fundoscopic changes are characterised by peripap-
illary telangiectatic microangiopathy or circumpapillary nerve
ﬁbre layer swelling (pseudooedema) in the early stages
(Fig. 6B), later followed by non-speciﬁc optic atrophy with
Figure 6 Ocular examination in mitochondrial disorders. (A) Macular pigmented retinopathy associated with the m.3243A>G
mutation. (B) The acute fundal appearance in Leber hereditary optic neuropathy is characterised by parapapillary nerve ﬁbre layer
swelling, tortuosity of the retinal vessels and disc hyperaemia (Yu-Wai-Man et al., 2009). (C and D) Optic disc appearance in DOA
highlighting total disc pallor and prominent temporal wedge of pallor typically observed in patients with OPA1 mutation (Yu-Wai-Man
et al., 2010b). RE, right eye; LE, left eye.
402 G.S. Gorman, R.W. Taylornerve ﬁbre layer drop out, especially in the papillomacular
bundle (Savini et al., 2005).
Although LHON is typically associated with isolated visual
loss, neurological and multisystem organ involvement has been
recognised in association with a multiple-sclerosis-like illness
(usually in women), dystonia, myelopathy, neuropathy, severe
encephalomyelopathy and cerebellar ataxia (Bhatti and
Newman, 1999; Horvath et al., 2000). One of three mtDNA
point mutations account for up to 95% of known cases of
LHON: m.3460G>A, m.11778G>A, m.14484T>C all of
which occur in mitochondrial-encoded structural subunits of
complex I. Younger age-at-onset (less than 15 years) and
mutation type appear to dictate visual outcome; patients with
the m.14484T>CMTND6 mutation have a better visual prog-
nosis with 60% attaining some visual improvement compared
to only 5% of those harbouring the m.11778G>A MTND4
gene mutation.
2.6. Dominant optic atrophy (DOA)
Autosomal dominant optic atrophy, with an overall prevalence
of 1:35,000 (Yu-Wai-Man et al., 2010b) is the most common
autosomal hereditary optic neuropathy and unlike LHON
exhibits no gender bias. DOA is a slowly progressive, painless,
bilateral, symmetrical visual loss. Onset is insidious and usu-
ally within the ﬁrst two decades of life. Visual loss is detected
usually between the ages of 4 and 6 years, with up to 84%
reporting visual disability by 11 years. There is a wide spec-
trum of visual acuity ranging from 20/20 to light perception;
however, the majority of patients retain vision of 20/200 or
better. Visual acuity decline may be progressive in up to halfof the patients. Defects in colour vision result from a general-
ised dyschromatopsia. The most frequent visual ﬁeld abnor-
malities in DOA are central, cecocentral, and paracentral
scotomas consistent with early involvement of the papilloma-
cular bundle, and may show a predilection for the superotem-
poral quadrant (Fig. 6C and D). Optic disc atrophy may be
subtle, diffuse or present as a ‘temporal wedge’ defect
(Yu-Wai-Man et al., 2009, 2010b). Mutations in the OPA1
gene – which is located on chromosome 3q28–29 – account
for 60–70% of all cases of DOA. To date, over 200 pathogenic
mutations in the OPA1 gene have been identiﬁed including
missense, nonsense, deletion/insertion, and splicing mutations.
In addition to OPA1, other loci have been identiﬁed. Optic
atrophy may be a feature of other mitochondrial syndromes
and has been reported in both MERRF and MELAS.
2.7. Retrochiasmal visual loss
Mitochondrial disease-related retrochiasmal visual loss is most
commonly associated with the MELAS syndrome. Stroke-like
episodes in MELAS have a propensity to affect primarily the
parietal and occipital lobes, resulting in damage to the visual
pathways and giving rise to homonymous hemianopia or cor-
tical blindness. Fundoscopic examination and pupillary re-
sponses are invariably normal.
3. Concluding remarks
The clinical spectrum of mitochondrial disorders is vast and
new patterns of disease are increasingly recognised. Diagnostic
accuracy has signiﬁcantly improved over the last decade with
Mitochondrial DNA abnormalities in ophthalmological disease 403our ability to detect many of the common mtDNA pathogenic
mutations non-invasively. However, muscle biopsy is often re-
quired to detect primary and secondary mtDNA abnormalities
and as such it remains the cornerstone of laboratory diagnostic
algorithms, particularly in patients with PEO. We suggest that
the diagnosis of mitochondrial disease should be considered in
all cases of ocular muscle dysmotility and in patients with vi-
sual failure of acute or insidious onset.
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